Infinity Pharmaceuticals, Inc. (INFI)

0.6400 -0.0100 (-1.54%) At close: 04:00PM EST

Infinity Pharmaceuticals, Inc.

1100 Massachusetts Avenue
Floor 4
Cambridge, MA 02138
United States
617 453 1000
https://www.infi.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Adelene Q. Perkins	Chairman & CEO	1.15M	N/A	1960
Dr. Stephane Peluso Ph.D.	Chief Scientific Officer	577.63k	N/A	1970
Dr. Robert Ilaria Jr., M.D.	Chief Medical Officer	643.54k	N/A	1961
Dr. Lawrence E. Bloch J.D., M.D.	Pres & Treasurer	N/A	N/A	1966
Ms. Melissa Hackel	VP of Fin.	N/A	N/A	N/A
Dr. Jeffery L. Kutok M.D., Ph.D.	Chairman of Scientific Advisory Board	N/A	N/A	1967
Mr. Seth A. Tasker J.D.	Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec.	N/A	N/A	1979
Jayne Kauffman	Sr. Exec. Coordinator	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Infinity Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.